[Neoadjuvant chemotherapy for esophageal cancer by administration of nedaplatin alone].

The possibility of safe implementation of neoadjuvant chemotherapy using nedaplatin (254-S) was investigated with the aim of improving the therapeutic results in advanced esophageal cancer patients. The subjects had usually undergone two courses of 254-S, 80 or 100 mg/m2, preoperatively, at intervals of 4 weeks. After chemotherapy, responses were evaluated, and resection was undertaken 4 weeks after the final administration. The subjects were 10 patients with untreated esophageal cancer. As a result of evaluation of responses of main lesions to chemotherapy, a partial response (PR) was observed in 3 patients, and a minor response 3, showing an efficacy rate of 30%. Pathological findings before treatment were determined by staining of a cell cycle marker (Ki-67). The 3 patients who were evaluated as PR (clinical efficacy) showed high rates of positivity for Ki-67 of 47.4%, 52.7%, and 86%, respectively. There were no serious complications and no death related to operation. The observations suggested that 254-S, which has little or no side effects including nephrotoxicity, can become the standard remedy for esophageal cancer instead of CDDP in future.
AuthorsS Hirata, E Yatsuyanagi, H Yamazaki, Y Sugimoto, S Kosiko, T Kokubo, Y Atsuta, T Sasajima, N Miyokawa
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 27 Issue 2 Pg. 221-6 (Feb 2000) ISSN: 0385-0684 [Print] JAPAN
PMID10700891 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Ki-67 Antigen
  • Organoplatinum Compounds
  • Tumor Suppressor Protein p53
  • nedaplatin
  • Aged
  • Antineoplastic Agents (administration & dosage)
  • Cell Cycle
  • Drug Administration Schedule
  • Esophageal Neoplasms (blood, drug therapy, pathology)
  • Female
  • Humans
  • Ki-67 Antigen (blood)
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Organoplatinum Compounds (administration & dosage)
  • Preoperative Care
  • Tumor Suppressor Protein p53 (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: